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n February 2000, a 7-valent pneumococcal conjugate vaccine (PCV) was licensed for use in the United States and recommended for universal use in children 23 months and younger. 1, 2 This vaccine has been effective in reducing the incidence of invasive pneumococcal disease (IPD) 3 in children and, although the evidence is weaker, it appears to be effective in reducing the incidence of pneumonia 4 and otitis media 3, 5 in children. The original U.S. cost-effectiveness analysis, published in 2000, estimated that the vaccine would cost $176,000 per lifeyear saved if only medical costs were included and $80,000 per life-year saved if caregiver work loss and other nonmedical costs were included. 6 To incorporate revised vaccine efficacy data, and to include more nationally representative cost and incidence data, a subsequent revision of that analysis was requested by the Centers for Disease Control and Prevention (CDC), which resulted in an estimate of $110,000 per lifeyear saved. 7 In a second revision of the model by Prosser et al, 8 the value of the vaccine in reducing morbidity (in addition to mortality) was estimated by surveying adults regarding the time they would be willing to tradeoff to avert pneumococcal disease in children. When these quality-of-life values were incorporated into the model, the cost per qualityadjusted life-year saved was reduced to less than $5000. Because data were lacking, none of these analyses took into account the possible effects of the vaccine in reducing disease in nonvaccinated individuals.
Nasopharyngeal carriage is a precondition for invasive and noninvasive pneumococcal respiratory disease and the vaccine reduces such carriage. 9 The reduced colonization in the nasopharynx in vaccinated children might reduce the transmission of pneumococci to nonvaccinated individuals, thereby reducing disease in those individuals. Recent national data indicate that rates of IPD among adults have decreased sharply since the introduction of the PCV. 10, 11 Given that most cases of pneumococcal disease and most deaths from pneumococcal disease in the United States occur in adults, 12 the inclusion of this potential "herd" effect is likely to significantly improve measures of the vaccine's cost-effectiveness.
The purpose of this study was to estimate the impact of PCV on disease and costs during its first 5 years of use in the United States, including the effects of reductions in disease among nonvaccinated children and adults. Unlike the cohort analysis used in the original cost-effectiveness study in which a single cohort was followed from birth to death, 6 we restrict our analysis to a 5-year period and simulate the vaccine's effect on the entire U.S. population during that time (including new cohorts of infants). This population-based approach is more amenable to the incorporation of herd effects than is a cohort analysis. By restricting the analysis to the first 5 years after introduction of the PCV, we avoid having to project changes in the herd effect as more infants become vaccinated. The approach is intrinsically conservative in that any herd effects are not included that might continue beyond the first 5 years even if no additional infants were vaccinated.
METHODS

Decision Analysis Model
The decision analysis model used for this analysis estimated the effects of the PCV on the entire U.S. population during the first 5 years of use of the PCV (2000 -2004) . To estimate the effects of the vaccine on vaccinated infants, we revised our previously developed cost-effectiveness model. 6, 7 That model, which was originally used to estimate the effects of PCV on a single birth cohort from birth to death, was revised to simulate the effects of PCV during the 5 years after its introduction for all infants born during the 5-year period. Consistent with the results of randomized trials, the PCV was assumed to prevent otitis media, pneumonia, and IPD in infants receiving the vaccine, and only IPD was assumed to potentially lead to death. A subset of IPD cases (meningitis) could result in permanent deafness or disability. The vaccine was assumed to be effective until the child's fifth birthday. In the current revised model, a certain percentage of children (based on National Immunization Program data) were assumed to receive the recommended shots according to schedule. The model did not address issues of partial vaccination. For those children who were assumed to have received their first 3 shots (at 2, 4 and 6 months of age) by the end of 2004, we included in the model the expected future reduction in pneumococcal disease up to their fifth birthday.
A separate model was used to estimate the effects of the vaccine in the nonvaccinated population for each year from 2000 to 2004. That population was grouped into the following age groups for analysis, based on consistency with a variety of data sources: 0 to Ͻ5, 5 to Ͻ15, 15 to Ͻ45, 45 to Ͻ65 and 65ϩ. In the final analyses, the results for vaccinated and nonvaccinated persons were combined.
Model Inputs and Assumptions
Population, children vaccinated and doses received. Population estimates by age group for each year from 2000 to 2004 were those of the U.S. Census Bureau. 13 Using data from the National Immunization Survey, 14 we estimated that about 70% of children born during our study period received 3 to 4 doses of PCV, amounting to approximately 14 million children receiving a total of 52 million doses. In the model, the other 30% of children were treated as if they were not immunized. Disease Incidence Rates. Table 1 shows the baseline (prevaccine) disease incidence rates. IPD and otitis media rates in children under 5 years of age are those of the original model. 7 The original model used a national estimate of all-cause pneumonia incidence. Here, instead of using the national estimate, we used the pneumonia incidence observed in the Kaiser Permanente population that was used in the original efficacy trial of PCV. 4 We did this because of the widely disparate practices with respect to the diagnosing of pneumonia and our concern that the efficacy estimates would not be applicable to incidence rates based on a completely different data source. The all-cause pneumonia incidence used here is higher than in the original cost-effectiveness model, but the vaccine efficacy used is lower (see Tables 1 and 2 ). The net effect was small. For persons over 15 years of age, all-cause hospitalized pneumonia incidence rates were based on the CDC's National Hospital Discharge Survey (NHDS), years 1997 to 1999 (International Classification of Diseases, 9th Revision, Clinical Modification ͓ICD-9-CM͔ codes 480 -486). 15 Because the published rates from the NHDS blended together the rates for all children under 15 years of age, our incidence rate for children 5 to 15 years of age were based on Kaiser Permanente, Northern California data (first-listed diagnosis with ICD-9-CM codes 480 -486, unpublished data, July 2005).
Baseline IPD rates in persons over 5 years of age were based on 1997 to 1999 data from the CDC's ABCs program. Annual rates of IPD were calculated in a manner similar to that described in Whitney et al, although additional surveillance areas were included. 10 Rates from the surveillance areas were adjusted to the age and race distribution of the United States. For 5 to Ͻ15 year olds, the 1997 to 1999 rates were 5.4, 4.3 and 4.5 per 100,000 persons. For 15 to Ͻ45 year olds, the rates were 11.0, 10.6 and 10.4. For 45 to Ͻ65 year olds, the rates were 20.6, 20.6 and 22.2. For persons over 65, baseline rates were 61.4, 59.4 and 60.5. For each age group, the mean rate over the 3-year period was used as the baseline rate in the analysis. IPD rates for 2000 to 2004, which were used to estimate the herd effect of the vaccine, were also based on the ABCs. Case-Fatality Rates. Case-fatality rates for IPD were based on the original cost-effectiveness model (for children under 5 years of age) 7 and data from the ABCs, 1997 to 1999. The ABCs data reflected an increase in case-fatality rates in years after PCV introduction. Because we assumed that changes in IPD rates in the postvaccine period were the result of the PCV, we also assumed that changes in case-fatality rates reflected the impact of PCV. The implication of the increased case-fatality rates was that cases averted by the vaccine would have been less likely to result in death had they occurred. Those cases that were not prevented by the vaccine were the ones more likely to result in death, thus driving up the case-fatality rates. For example, the baseline IPD casefatality rate (from years 1997-1999) in persons over 65 was approximately 18% and rose to 21% in the years 2000 to 2004 (not shown). Assuming the increase to 21% was the result of the more severe cases remaining in the postvaccine years, we used our estimates of the number of cases averted by the vaccine to determine that the baseline case-fatality rate of the averted cases was approximately 11%. Pneumonia cases averted by the herd effect of PCV were assumed to have the same case-fatality rates as other pneumonia cases. Vaccine Efficacy and Herd Immunity. Table 2 shows the vaccine efficacy rates against pneumococcal disease in chil- Empty cells indicate that estimate was not used in analyses. Clinically diagnosed outpatient pneumonia Not used in base case analysis; used in sensitivity analysis only. For children under 5, the indirect effect of the vaccine against pneumonia was assumed to be the same proportion of the direct effect as it was for invasive disease.
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For persons over 5 yr of age, only hospitalized pneumonia was included in the analysis, and the herd effect was assumed to be the same as for invasive disease but was adjusted for the estimated percent of hospitalized pneumonia that is pneumococcal in origin (12.6%, based on Marston et al.
17
).
Adapted from Prosser LA, et al. ).
# Empty cells indicate that estimate was not used in analyses.
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dren receiving the vaccine. Except for pneumonia, the efficacies used here are the same as the original model 7 and were based on trial results and expert panel opinion. Pneumonia efficacy was revised based on subsequent trial results. 4 The percent reductions in IPD among nonvaccinated persons over 5 years of age assumed to be the result of the herd effect of the PCV are also shown in Table 2 . These were based on the observed rates of IPD in the postvaccine years compared with the average of the rates from 1997 to 1999. Changes were assumed to be the result of the introduction of the PCV and, because they are based on observed rates over the 5-year period, reflect increasing vaccine penetration rates over this time. For children under 5 years of age, the herd effect was derived by estimating the actual reduction in IPD cases (based on the ABCs data) and comparing that with the estimated reduction in cases resulting from the direct effect of the vaccine. The difference was assumed to be the result of the indirect effects of the vaccine.
Because pneumococcal pneumonia is only a portion of all-cause pneumonia, and because of the lack of specificity of the pneumonia diagnosis, it is very difficult to use nationally available data to discern clear and compelling changes in the incidence of pneumonia since the introduction of PCV. Given this lack of empiric data, we restricted the base case analysis to include only the indirect effects of the vaccine on IPD. Nevertheless, because the potential indirect effects on pneumonia may be significant, we performed a sensitivity analysis, which included an estimate of the effect of the vaccine in reducing pneumonia in nonvaccinated persons. In children under 5 years of age, we assumed that the indirect effect of the vaccine against pneumonia was the same proportion of the direct effect as was the case for IPD. In persons over 5 years of age, we restricted the analysis to hospitalized pneumonia (for which we had national incidence data), assumed that 12.6% of all-cause hospitalized pneumonia was pneumococcal, 16 and that the indirect effect on pneumococcal pneumonia was the same as that of IPD. Quality-of-Life Estimates. Quality-adjusted life-years saved for each averted case of pneumococcal disease in children under 5 were derived from the discounted median community values reported by Prosser et al (Table 2) . 8 We are aware of no studies measuring quality of life for adults during episodes of IPD or hospitalized pneumonia. We therefore assumed that a reduction in quality of life occurred only during the hospital stay for the condition, and that quality of life during that stay was equivalent to "fair" health for persons "unable to perform self-care activities of daily living without the help of other persons," as these are defined in a CDC, Healthy People 2000 publication. 17 Average hospital duration for IPD and pneumonia cases were based on Kaiser Permanente data and ranged from 3 to 5 days depending on age and disease condition. Similar to the approach used by Sisk et al, 18 in their cost-effectiveness analysis of pneumococcal polysaccharide vaccination in the elderly, we adjusted expected years of life for the quality of life at each age using years of healthy life measures based on the 1990 National Health Interview Survey (Table 2) . 17 This method, although not ideal (because these weights were not measured empirically from a community sample), has been suggested as a promising "placeholder" source for health status measures in which direct measures are lacking. 19 Costs. The costs of pneumococcal disease episodes in children under 5 were adapted from the original cost-effectiveness model and converted to 2004 U.S. dollars using the Consumer Price Index (Table 3) . Costs for pneumonia and IPD episodes were based on Kaiser Permanente Northern California data. The mean price paid for a single dose of PCV was $52 (V. Ciuryla, Wyeth Pharmaceuticals). All costs and benefits (life-years and disease episodes) were discounted at 3%. Base Case Analysis. Our base case analysis incorporated all the effects included in the original cost-effectiveness model for children under 5 years of age plus the observed reductions in IPD in persons over 5 years of age and the estimated reduction in IPD in nonvaccinated children under 5 years of age. No quality-of-life adjustments were included in the base case and no potential effects on pneumonia in nonvaccinated persons were included. To reflect, as much as possible, the methodology of the original cost-effectiveness analysis, the base case included time-related costs (such as work loss) incurred by the parents of children under 5 years of age, but not the time-related costs of patients themselves, regardless of age.
Sensitivity Analyses
We performed the following sensitivity analyses in which the following changes were made, one at a time, to the base case: 1) the reduction in IPD among nonvaccinated persons over 5 years of age was 50% of that in the base case; 2) the potential herd effect relating to pneumonia for persons over 5 years of age was included at the "full" estimated effect and at 50% of the estimated effect; 3) only medical costs were included; 4) the vaccine was assumed to have no effect on otitis; and 5) quality-of-life adjustments were included to calculate the estimated cost per quality-adjusted life-year saved.
RESULTS
Effect of the Vaccine on Pneumococcal Disease in Nonvaccinated Persons
Data from the ABCs indicate that the rate of IPD in the nonvaccinated population fell considerably in the 5 years after the introduction of PCV. By 2004, rates fell by 38% for persons 5 to Ͻ15 years of age, 47% for persons 15 to Ͻ45 years of age, 20% for persons 45 to Ͻ65 years of age and 36% for persons 65 and older (Table 2 ). In nearly all cases, disease rates declined steadily in each year from 2000 to 2004. Among children less than 5 years of age, the ABCs data combined with the model's estimate of the direct effects of the vaccine showed a considerable herd effect in this population (5% reduction in IPD in 2000 increasing to 68% by 2004, which is nearly the same as the average direct effect of the vaccine in that age group).
Base Case Cost-Effectiveness
Before incorporating any herd effects in the model, the PCV in this analysis was estimated to have averted 38,000 cases of IPD during its first 5 years of use at a cost of $33,000 per IPD case averted and $112,000 per life-year saved (Table  4) . After incorporating the reductions in IPD for nonvaccinated individuals, the vaccine averted 109,300 cases of IPD at a cost of $5500 per IPD case averted and $7500 per life-year saved. The net cost per child vaccinated was reduced from $91 to $43 when herd protection was incorporated. Although rates of IPD were much higher in persons over 65 years of age, more life-years were saved in persons under 65.
Sensitivity Analyses
The base case results were relatively insensitive to changes in the main assumptions (Table 5 ). When we assumed that only half of the observed reduction in IPD rates among nonvaccinated persons during the 2000 to 2004 period was the result of PCV, the cost per life-year saved was $18,400. When we incorporated our estimate of the potential impact of herd immunity on pneumonia, the vaccine became cost-saving. This was true even when we reduced that effect by half. If only medical costs were included in the analysis, the cost per life-year saved was $17,600, and if we assumed the vaccine had no effect on otitis media, the cost per life-year saved was $24,200. When we simultaneously reduced the IPD herd effect by half, excluded nonmedical costs and assumed no effect on otitis media, the cost per life-year saved was $48,600. When adjustment was made for estimated quality of life, the cost-effectiveness ratio decreased, from $7500 per life-year saved in the base case to $3500 per quality-adjusted life-year saved. 
DISCUSSION
The Active Bacterial Core Surveillance data indicate that the rates of invasive pneumococcal disease in persons who have not been vaccinated with PCV have decreased substantially in the 5 years since the introduction of PCV in 2000. Given that these data are limited, observational time series, we cannot be certain of the causes of these declines. Nevertheless, it seems unlikely that these substantial declines in the rates of IPD in all age groups starting in 2000 could be entirely the result of chance or factors other than the herd protection elicited by PCV. That there is a plausible biologic mechanism for the declines, and that the declines following the 1997 to 1999 period have increased in each year since 2000, supports this conclusion. In addition, other analyses of ABCs data show the decline in rates for most age groups is limited to disease caused by the serotypes included in the vaccine. 10, 20 Our analysis shows that the incorporation of these indirect effects on nonvaccinated persons has a substantial impact on the cost-effectiveness of the vaccine. This is true even if only half of the observed decrease in IPD rates in nonvaccinated persons is the result of the indirect effects of the vaccine. The original cost-effectiveness analysis (using a cohort analysis somewhat different from this populationbased analysis) concluded that the vaccine would cost $80,000 per life-year saved 6 and a revision of that analysis at the request of the CDC concluded the vaccine would cost $110,000 per life-year saved. 7 Now that we have incorporated evidence of the indirect effect of the vaccine on nonvaccinated persons, we conclude that over the first 5 years of use, the vaccine has cost $7500 per life-year saved. Although PCV was shown to be relatively cost-effective in terms of cost per quality-adjusted life-year saved even before the incorporation of indirect effects, 8 we see now that the vaccine is cost-effective even by the much more conservative measure of cost per life-year saved, which does not incorporate any morbidity associated with the vaccine's apparent effectiveness in preventing otitis, pneumonia and IPD cases that do not result in death.
Data from the National Immunization Program indicate that approximately 70% of children born during the 5 years of the study received 3 or more doses of PCV and we further assumed that these children received a booster dose at 12 months of age if they were that old before the end of 2004. We did not attempt to estimate or take into account children who may have received less than 3 doses because these data were not available to us throughout the time period and there are no very reliable estimates of the vaccine's efficacy when used this way. On the other hand, many children who received 3 doses of the vaccine did not go on to receive the booster dose. 21 Thus, we believe that our estimate of the number of doses used in the United States (and thus the most important component of cost) is reasonable and deviations from our assumption are unlikely to have a significant impact on the results.
There is evidence that the PCV has caused an increase in pneumococcal disease caused by nonvaccine serotypes through "serotype replacement." 11 Because our assumptions regarding rates of disease in the nonvaccinated were based on observed rates of IPD regardless of serotype, our results implicitly incorporate any serotype replacement that might be taking place. However, if serotype replacement increases over time, it is possible that the efficacy of the vaccine-both for the vaccinated and nonvaccinated populations-could decline in the future. Because our results describe what happened only in the first 5 years after the introduction of the vaccine, and are not based on assumptions about the effects in future years, they are unaffected by this issue.
Cost-effectiveness estimates have become a key component of decisions on whether to adopt public health measures. Although useful, such estimates are often of necessity made using assumptions and expert opinion when data are lacking. Our results show that the cost-effectiveness of PCV in actual use has likely been much more favorable than predicted by estimates developed before the vaccine was licensed and may even be cost-saving if the indirect effect extends to reducing pneumonia in the nonvaccinated population. Incorporate estimates of quality of life for cost per quality-adjusted life-year saved 3500 *Sensitivity analyses are each independent of the one before; they are Љone-wayЉ analyses except where noted. IPD indicates invasive pneumococcal disease.
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